研究单位:[1]Hebei Medical University Fourth Hospital河北医科大学第四医院
研究目的:
The purpose of this study is to assess efficacy and safety of patients who receive camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally advanced ESCC.